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Abstract: Optic nerve hypoplasia (ONH) is a congenital optic nerve abnormality caused by underdevel-
opment of retinal ganglion cells (RGCs). Despite being a rare disease, ONH is the most common optic
disc anomaly in ophthalmological practice. So far, mutations in several genes have been identified as
causative, however many cases of ONH remain without a molecular explanation. The early transcription
factor atonal basic-helix-loop-helix (bHLH) transcription factor 7 (ATOH7) is expressed in retinal progen-
itor cells and has a crucial role in RGC development. Previous studies have identified several mutations in
the ATOH7 locus in cases of eye developmental diseases such as nonsyndromic congenital retinal nonat-
tachment and persistent hyperplasia of the primary vitreous. Here we present two siblings with a pheno-
type predominated by bilateral ONH, with additional features of foveal hypoplasia and distinct vascular
abnormalities, where whole-exome sequencing identified two compound heterozygous missense mutations
affecting a conserved amino acid residue within the bHLH domain of ATOH7 (NM145178.3 : c.175G >
A; p.(Ala59Thr)andc.176C > T ; p.(Ala59V al)).ATOH7expressionconstructswithpatientsinglenucleotidevariantswerecl
bindingofATOH7variants, resultingintotallossoftranscriptionalactivationofluciferasereportergeneexpression.Thesef
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Optic nerve hypoplasia (ONH) is a congenital optic nerve abnormality caused by 
underdevelopment of retinal ganglion cells (RGCs). Despite being a rare disease, ONH is the 
most common optic disc anomaly in ophthalmological practice. So far, mutations in several 
genes have been identified as causative, however many cases of ONH remain without a 
molecular explanation. The early transcription factor atonal basic-helix-loop-helix (bHLH) 
transcription factor 7 (ATOH7) is expressed in retinal progenitor cells and has a crucial role in 
RGC development. Previous studies have identified several mutations in the ATOH7 locus in 
cases of eye developmental diseases such as nonsyndromic congenital retinal nonattachment 
and persistent hyperplasia of the primary vitreous. 
Here we present two siblings with a phenotype predominated by bilateral ONH, with 
additional features of foveal hypoplasia and distinct vascular abnormalities, where whole-
exome sequencing identified two compound heterozygous missense mutations affecting a 
conserved amino acid residue within the bHLH domain of ATOH7 
(NM_145178.3:c.175G>A; p.(Ala59Thr) and c.176C>T; p.(Ala59Val)). ATOH7 expression 
constructs with patient single nucleotide variants were cloned for functional characterization. 
Protein analyses revealed decreased protein amounts and significantly enhanced degradation 
in the presence of E47, a putative bHLH dimerization partner. Protein interaction assays 
revealed decreased heterodimerization and DNA-binding of ATOH7 variants, resulting in 
total loss of transcriptional activation of luciferase reporter gene expression. These findings 
strongly support pathogenicity of the two ATOH7 mutations, one of which is novel. 
Additionally, this report highlights the possible impact of altered ATOH7 dimerization on 








































































































Congenital visual impairment can be caused by optic nerve hypoplasia (ONH; OMIM 
#165550), which has been recognized as one of the most common causes of childhood 
blindness with a prevalence of 2.4-17.3 cases per 100 000 (1–3). ONH is the most common 
and severe type of congenital optic nerve anomaly, characterized by small, normal, grey or 
pale appearing optic nerves with a typical “double-ring sign” on funduscopy associated with 
abnormalities in size and distribution of the retinal vessels (4). It is estimated that 
approximately 80 % of patients suffering from bilateral ONH are legally blind, however the 
phenotype is highly variable and ranges from nearly normal vision to no perception of light 
(5). Although ONH does occur as an isolated trait, most cases are associated with 
developmental abnormalities such as anterior segmental defects of the eye, septo-optic 
dysplasia, hemispheric or pituitary abnormalities, developmental delay, and autism spectrum 
disorders (4,6–8).  
ONH typically presents as sporadic cases, many of which remain without a clear molecular 
diagnosis. With advances in high-throughput sequencing technology over the past decade, 
several ONH-associated mutations have been reported, a majority of which occur in neural or 
retinal transcription factor genes (9). HESX1 mutations have been identified as a rare cause of 
ONH with septo-optic dysplasia and hypopituitarism, but also documented in patients without 
ONH (10–13). PAX6 mutations were described in patients with bilateral ONH as well as 
patients with unilateral or bilateral optic nerve aplasia (ONA) (6). SOX2 mutations were 
found in several patients suffering from ONH and either brain malformations or 
microphthalmia/anophthalmia (8). Heterozygous NR2F1 mutations have been detected in 
several patients suffering from Bosch-Boonstra-Schaaf Optic Atrophy Syndrome (BBSOAS), 
which includes ONH (14). Heterozygous mutations in OTX2 are the second most common 







































































































(15,16). A homozygous missense variant in VAX1 has also been reported in a patient with 
microphthalmia, ONH, and brain malformations (17). 
Atonal basic helix-loop-helix (bHLH) transcription factor 7 (ATOH7) encodes a 152 amino 
acid protein, which forms a helix-loop-helix domain responsible for protein dimerization as 
well as a DNA-binding basic domain located within the first helix (18). The mouse ortholog 
Math5 has been identified as a crucial factor in the development of the retina, specifying the 
differentiation of retinal ganglion cells (RGCs) from retinal progenitor cells (RPCs) (19). 
Math5
-/-
 mice display normal sized eyes without optic nerves, chiasms, or RGCs but with an 
increased number of cone photoreceptors (20). Transgene expression of ATOH7 in human 
induced pluripotent stem cells (hiPSCs) has been likewise demonstrated to drive 
differentiation of RGCs (21). Several SNPs in the 5’-UTR of ATOH7 were found to be 
associated with optic disc size in a genome-wide association study (22). 
ATOH7 is implicated in several developmental eye disorders. Mutations in a remote upstream 
transcription enhancer region of ATOH7 were associated with nonsyndromic congenital 
retinal nonattachment (NCRNA; OMIM # 221900) (23,24). A missense point-mutation in the 
DNA-binding domain of ATOH7 (p.(Asn46His)) was shown to lead to persistent hyperplasia 
of the primary vitreous (PHPV; OMIM #221900) (25). This replicates a previous finding in 
Math5
-/-
 mice, in which lack of RGCs resulted in abnormal retinal vessel development and 
persistent hyaloid vasculature (20). A homozygous frameshift mutation in the ATOH7 coding 
region has been identified in two Turkish siblings suffering from various developmental eye 
defects including, amongst others, microphthalmia, persistent fetal vasculature (PFV; OMIM 
#221900), ONH, and NCRNA (26). Khan et al. also described a severe phenotype in several 
affected members of a consanguineous family from Pakistan caused by a homozygous 







































































































microphthalmia, dense corneal opacities, retrolental mass, and severe retinal and vitreous 
dysplasia. 
Although a potential link to ONH is implied by its occurrence as part of various global eye 
phenotypes caused by ATOH7 mutations, the role of this transcription factor in ONH remains 
unclarified. In a study including 34 ONH patients with or without septo-optic dysplasia, six 
sequence variants were identified within the untranslated region of the ATOH7 locus as well 
as one intronic variant (27), but no mutations in the coding region. In another study, Sanger 
sequencing of 12 patients suffering from ONH or ONA identified two heterozygous missense 
variants p.(Ala47Thr) and p.(Arg65Gly) in ATOH7 (22). However, in vitro functional 
characterization could not confirm these variants as causative of the phenotype (25). 
Here we present two compound heterozygous missense mutations in ATOH7, 
NM_145178.3:c.175G>A (p.(Ala59Thr)) and c.176C>T (p.(Ala59Val)), which segregate with 
an ocular phenotype dominated by bilateral ONH in a Swiss family with two affected siblings. 
Glial tissue was present in one of the patients. This may be interpreted as a variant of PFV. 
Findings of abnormal retinal vasculature, including tortuosity and incomplete peripheral 
vascularization (the far peripheral retina could only be examined in one patient), were present 
upon examination and may be an indirect result of the interruption of RGC development by 
the described ATOH7 mutations. As Provis pointed out, the primary retinal vasculature 
develops at the RNFL/ RGC interface (28). Thus, a disturbance of this interface will interrupt 
retinal vessel development. This is evidenced clinically by the frequent association of optic 
disc anomalies with abnormal retinal vessel distribution. 
Additionally, foveal hypoplasia (FVH) was present in the affected siblings as well as the 
father. A heterozygous missense single nucleotide variant (SNV) in OPA3, 
NM_001017989.2:c.43G>C (p.Gly15Arg), was found in all family members presenting with 







































































































vitro functional assessment of the respective mutant ATOH7 proteins expressed in HEK293T 
cells was performed, addressing protein expression, stability, and function. As bHLH 
transcription factors primarily act as heterodimers with other bHLH proteins, the bHLH 
transcription factor E2-alpha isoform E47, encoded by the transcription factor 3 (TCF3) gene 
(29), was co-expressed as a putative binding partner in functional assays. Our findings 
indicate that the patient-derived ATOH7 sequence variants ((p.(Ala59Thr) and p.(Ala59Val)), 
which affect a highly conserved amino acid residue within the helix-loop-helix (HLH) 
domain, have a significant impact on protein stability, heterodimerization, and DNA-binding, 
as well as a total loss of ATOH7-induced transcriptional activation. The presented ONH cases 
are the first report of compound heterozygous ATOH7 missense mutations associated with a 
non-syndromic ocular phenotype dominated by ONH. Furthermore, this report highlights the 
impact of ATOH7 protein dimerization on protein stability and function. In the light of these 










































































































Severe bilateral optic nerve hypoplasia and foveal hypoplasia in two siblings with poor 
vision 
The index patient was referred to the Department of Ophthalmology at the University 
Hospital of Zurich at the age of seven years due to unexplained low vision despite corrective 
glasses and amblyopia treatment. The patient had a history of esotropia observed at the age of 
two-and-a-half years and myopic astigmatism observed at the age of four years. No 
extraocular manifestations were present. The index patient’s younger sister was referred at the 
age of three due to reduced visual function. The patient had a history of esotropia at the age of 
two years. The two older siblings and the non-consanguineous parents of Caucasian ancestry 
had no history of visual disabilities. The affected children had no history of prematurity, were 
cognitively normal for their age, and had excellent grades at school during the observation 
period. 
Initial examination of the index patient revealed best-corrected visual acuity at distance 
20/100 (RE) and 20/200 (LE), and at near 20/80 (RE) and 20/100 (LE) at age seven years. 
Left microesotropia was present. Refraction showed myopic astigmatism. Examination of the 
younger affected sibling revealed that visual acuity at near was reduced to 20/200 (RE) and 
20/100 (LE) at three years of age. Orthoptic assessment diagnosed a right microesotropia with 
eccentric fixation superior to the presumed foveola. Refraction showed hyperopic 
astigmatism. Neurological and endocrinological assessment was normal in both siblings. 
Visual acuity was stable during the observation period up to age 11 and six in the index 
patient and her sister, respectively. The remaining family members had a normal visual 







































































































Dilated fundus examination of the index patient and her younger sister demonstrated bilateral 
severe ONH as well as signs of FVH and abnormal vessel distribution with tortuosity and 
drag of the retinal vessels towards the temporal side (Fig. 1A-B). Imaging of the peripheral 
retina revealed incomplete vascularization of the far peripheral retina, without visible signs of 
neovascularization, in the affected sibling (unfortunately the index patient was not available 
for further imaging) (Suppl. Fig. 1); for this reason, as well as the ages of the patients, no 
angiography was performed. There was no sign of microphthalmia or microcornea. Optical 
coherence tomography (OCT) revealed significantly reduced thickness of the retinal nerve 
fiber layer (RNFL) as well as the ganglion cell and inner plexiform layers (GCIPL) in the two 
affected siblings (Table 1). The index patient and her father showed also signs of grade one 
foveal hypoplasia with absent extrusion of plexiform layers and a shallow foveal pit (Fig. 1G 
and C, respectively), whereas the affected sibling showed grade two hypoplasia with absent 
extrusion of plexiform layers and absent foveal pit (Fig. 1H). Structural grading of foveal 
morphology was performed according to Thomas et al. (30). The other family members 
exhibited normal OCT findings of the optic nerve and macular region (Table 1; Fig. 1D-F). 
Cerebral magnetic resonance imaging (MRI) of the index patient confirmed severely 
hypoplastic optic nerves within small optic nerve sheaths (Fig. 1I and J) in comparison to a 
control (Fig. 1K and L). No abnormalities of midline structures or other brain areas were 
observed. No MRI was performed on the affected younger sibling because of the similarity 
between her fundus changes and those of her sister, her normal developmental state, and 
because successful MRI scan acquisition would have required sedation due to her age. 
Compound heterozygous ATOH7 missense variants segregate with optic nerve 
hypoplasia 
Whole exome sequencing (WES) of the index patient and the affected sister revealed two 







































































































p.(Ala59Thr) and c.176C>T; p.(Ala59Val), of which p.(Ala59Thr) is not present in genome 
databases and p.(Ala59Val) is a rare variant with a minor allele frequency (MAF) of one in 25 
000 in non-Finnish European population (NFE). No other rare variants were detected in a 
gene panel consisting of a total of 29 genes (Suppl. Table 1) previously associated with ONH 
(8,10,14,16,17,26,31–46) and/or FVH (40,47–51). 
The discovered ATOH7 variants segregated with optic nerve hypoplasia within the family 
(Fig. 2A). Sanger sequencing confirmed compound heterozygosity in the affected siblings and 
presence of heterozygous variants in the unaffected family members (Fig. 2B). The unaffected 
parents as well as the two unaffected siblings were all carriers of either of the two variants. 
Both variants were predicted likely to be disease causing by three different algorithms (Table 
2), affecting a highly conserved amino acid residue within the first helix of the bHLH domain 
of ATOH7 (Suppl. Fig. 2). High-throughput sequencing of a 9.3 kb long-range PCR product 
spanning the entire ATOH7 locus was performed on all family members and excluded 
additional rare sequence variants, in introns as well as in flanking regions. 
Genetic testing for foveal hypoplasia in the father 
The father of the two affected siblings revealed FVH upon OCT examination. This was also 
seen in the two affected siblings. In order to investigate whether there was an independent 
genetic reason for this finding in the father, we performed WES. As no additional rare 
variants were found in candidate genes associated with ONH and/or FVH (Suppl. Table 1), 
the gene list was extended to include our institute’s gene panel for eye diseases 
(https://www.medmolgen.uzh.ch/de/services/Hauptgene.html; accessed 01.07.2019). The 
extended filtering revealed a rare heterozygous OPA3 exon one sequence variation, with a 
MAF of one in 100 000 in the NFE population, which was discovered in the father 
(NM_001017989.2: c.43G>C; p.(Gly15Arg)) and was also present in the affected siblings. 







































































































carrier (Suppl. Fig. 3). The OPA3 variant was predicted likely to be disease causing by three 
different algorithms (Table 2). However, since it is also present in the unaffected sister, it may 
not be the causative sequence variant for the clinical feature of foveal hypoplasia in this 
family. Alternatively, incomplete penetrance may explain the unaffected mutation carrier. 
Reduced protein amounts of ATOH7 variants in the presence of a dimerization partner  
Protein amounts of transgenic V5-tagged ATOH7 in HEK293T cells were measured by semi-
quantitative western blot (Fig. 3 and Suppl. Fig. 4). To simulate heterozygosity, both patient-
derived variants were co-expressed with wildtype ATOH7. The previously characterized 
ATOH7 mutation p.(Asn46His) was included in the experiments as a loss-of-function control 
(25). As an additional control, an artificial missense variant (NM_145178.3:c.176C>G; 
p.(Ala59Gly)) was constructed, with high biochemical similarity of the substituted amino acid 
residue to its wildtype counterpart.  
No statistically significant difference in variant protein amount was detected in comparison to 
wildtype ATOH7 (Fig. 3A). The bHLH transcription factor E2-alpha isoform E47, encoded 
by TCF3, represents a putative dimerization partner of ATOH7 (25). In the presence of co-
expressed E47, a significant decrease in protein amounts of patient variants was observed 
relative to wildtype ATOH7, suggesting reduced protein stability of ATOH7 when forming 
heterodimers with E47 (Fig. 3B). Reduced amounts were observed to a lesser degree for the 
artificial variant, the loss-of-function control p.(Asn46His), as well as for the patient variants 
co-expressed with wildtype ATOH7. Treatment with proteasome inhibitor MG-132 
completely restored the relative ATOH7 variant protein amounts (except for p.(Ala59Val)) 







































































































Co-expression of E47 increases proteasome-mediated degradation of variant ATOH7 
protein 
Cycloheximide (CHX) time course assays were performed in order to verify the suggested 
increased protein turnover of ATOH7 variants (Fig. 4 and Suppl. Fig. 5). HEK293T 
expressing V5-tagged ATOH7 were pretreated with CHX to block protein synthesis, and 
protein amounts were quantified by western blot at time points zero to four hours post CHX 
addition. No significant difference in protein stability was observed for any of the ATOH7 
variants in the absence of the putative dimerization partner E47 (Fig. 4A), while co-
expression of E47 significantly increased the turnover rate of the ATOH7 patient variants. 
The loss-of-function variant p.(Asn46His) and the synthetic variant p.(Ala59Gly) 
demonstrated similar turnover rates, which were significantly increased compared to wildtype 
ATOH7 but significantly slower compared to ATOH7 patient variants (Fig. 4B). Treatment 
with MG-132, an inhibitor of proteasomal degradation, resulted in normalization of all protein 
variant turnover rates relative to wildtype ATOH7. This confirmed proteasome-mediated 
degradation as the main mechanism for reduced protein amount of ATOH7 variants in 
presence of a putative dimerization partner (Fig. 4D). 
Reduced heterodimerization of patient-derived ATOH7 with E47 
Protein-protein interaction ELISA was performed in order to investigate the potential impact 
of ATOH7 patient variants on bHLH protein dimerization. No significant enrichment of either 
V5-tagged wildtype or variant ATOH7 could be detected when exposed to antibody 
immobilized c-Myc-tagged ATOH7 protein (Fig. 5A-B). A significant enrichment of V5-
tagged wildtype ATOH7 was detected in the presence of antibody immobilized c-Myc-tagged 
E47 (Fig. 5C), representing ATOH7-E47 heterodimer formation in vitro. The loss-of-function 







































































































significant heterodimerization compared to background control. All ATOH7 variants 
exhibited significantly reduced heterodimerization compared to wildtype ATOH7. 
Patient-derived ATOH7 variants show reduced DNA-binding 
To address the impact on DNA-binding ability of the ATOH7 variants, a DNA-protein 
interaction enzyme-linked immunosorbent assay (ELISA) was established. Double-stranded 
DNA containing seven consecutive canonical E-box sequences (CAGGTG) was immobilized 
to immunoassay plates by biotin-streptavidin interaction. HEK293T lysate containing 
transgenic V5-tagged ATOH7 was incubated with or without lysate containing E47. In 
concordance with dimerization assays, no DNA-binding of V5-tagged wildtype or variant 
ATOH7 protein could be detected in the presence of immobilized E-box (Fig. 6A). A 
significant E-box dependent DNA-binding was observed with wildtype ATOH7 in the 
presence of E47, suggesting DNA-binding of ATOH7-E47 heterodimers (Fig. 6B). Except for 
the synthetic variant p.(ala59Gly), all ATOH7 protein variants exhibited significantly reduced 
DNA-binding compared to wildtype ATOH7. DNA-binding of the combination of p.(Ala59) 
variants, as well as the previously published p.(Asn46His), did not show significant 
enrichment compared to negative control (scrambled E-box), suggesting potential loss of 
DNA-binding ability. Additionally, the p.(Asn46His) showed significantly lower enrichment 
compared to all other tested variants. 
ATOH7 patient-derived protein variants represent loss-of-function mutations 
Since the biological function of ATOH7 is transcriptional activation or regulation of target 
genes, we performed reporter gene assays. Dual luciferase assays were carried out in 
HEK293T in order to investigate whether or not the ATOH7 patient-derived variants are 
capable of transcriptional activation. HEK293T were transfected with plasmid constructs 
carrying the firefly luciferase reporter gene regulated by a minimal promoter containing seven 







































































































Assessment of cells co-expressing wildtype ATOH7 displayed a significant increase of 
luciferase expression over background, which was further enhanced by co-expressing E47 
(Fig. 7A), indicating functional ATOH7-E47 dimers. In contrast, patient-derived ATOH7 
protein variants did not show a statistically significant transcriptional activation of reporter 
gene expression, regardless of co-expression with E47. Similarly, the loss-of-function variant 
p.(Asn46His) did not show any transcriptional activation, which is consistent with previously 
published data (25). Interestingly, a significant decrease of base level luciferase activity could 
be seen when expressing p.(Asn46His) in presence of E47.  
The artificial variant p.(Ala59Gly) displayed statistically significant transcriptional activation, 
however this was reduced in magnitude relative to wildtype ATOH7 (Fig. 7B). Co-expression 
of wildtype ATOH7 and patient variants, mimicking the carrier status of the parents, 
displayed a minor reduction in luciferase reporter expression compared to wildtype ATOH7. 
In order to account for potentially reduced ATOH7 variant protein expression when co-
expressing E47, luciferase assays were also carried out on MG-132 treated samples (Suppl. 
Fig. 6). The loss of transcriptional activation of the ATOH7 patient variants remained. 
Confocal microscopy of fluorescently stained V5-tagged ATOH7 was additionally performed 
in order to verify that the measured loss of transcriptional activation is not due to protein 









































































































Patient-derived ATOH7 variants affect protein heterodimerization 
ATOH7 is a class II bHLH transcription factor, characterized by tissue specific expression, 
low capability of homodimerization, and favored heterodimerization with class I bHLH 
transcription factors, also known as E proteins (52). The latter characteristics support our 
observation that wildtype ATOH7 protein could not be enriched in ELISA assays through 
protein homodimerization (Fig. 5) nor through E-box DNA-binding (Fig. 6) in the absence of 
the putative heterodimerization partner E47. This finding is supported by the results of 
previous work by Prasov et al., who observed ATOH7-E47 protein heterodimers but not 
ATOH7 homodimers by means of electrophoretic mobility shift assay (EMSA) (25). 
Interestingly, we were able to measure E-box mediated transcriptional activation induced by 
wildtype ATOH7 in the absence of E47 co-expression (Fig. 7). It is likely that endogenously 
expressed E47 and/or other class I bHLH binding partners may have contributed to 
transcriptional activation through heterodimerization with transgenic ATOH7. It is also 
possible that short-lived functional homodimers are stable inside the nucleus of a living cell 
but not in cell-free conditions. 
Our findings suggest that the two characterized ATOH7 missense variants at protein position 
59 lead to significantly reduced heterodimerization. The 59
th
 amino acid position of ATOH7 
is a highly conserved residue within the HLH domain, important for bHLH transcription 
factor dimerization. A closely related homolog of ATOH7 is the class II bHLH transcription 
factor NEUROD1. The crystal structure of the E47-NEUROD1 heterodimer has been 
previously identified through x-ray crystallography (53). The alanine at the 59
th
 position of 
ATOH7 coincides with alanine at position six of the first helix in the NEUROD1 amino acid 







































































































interface and thus supports our finding that mutations in this position have a deleterious 
impact on heterodimerization. 
Interestingly, the previously described loss-of-function variant p.(Asn46His) did not show 
significant heterodimerization, despite being located within the DNA-binding basic domain of 
ATOH7 and thus outside of the HLH domain. It is possible that the substitution of asparagine 
for histidine, which introduces an imidazole ring and thus a net positive charge of the amino 
acid residue, may influence the secondary protein structure and thus the overall ability of the 
variant ATOH7 monomer to form dimers with E47. 
ATOH7 heterodimerization affects DNA-binding and transcriptional activation 
Interestingly, both of the patient-derived ATOH7 variants also resulted in decreased/lost 
ability of the ATOH7 protein to bind E-box DNA (Fig. 6), despite the fact that these amino 
acid substitutions are located outside the DNA-binding basic domain. This may be explained 
as a direct consequence of impaired and decreased heterodimerization, which disrupts DNA-
binding of bHLH proteins (54). These functional aberrations ultimately lead to loss of 
transcriptional activation of the two ATOH7 patient-derived variant proteins, as observed in 
luciferase reporter assays (Fig. 7).  
The artificial ATOH7 p.(Ala59Gly) variant was used as a control throughout the functional 
characterization. Due to the similar properties of alanine and glycine, we expected little or no 
impact on protein function. The variant displayed reduced dimerization and DNA-binding, 
however transcriptional function/activation was retained and this variant may therefore be 
considered a hypomorphic allele. 
In contrast, the published p.(Asn46His) variant, located in the DNA-binding basic domain, 
failed to bind DNA and activate transcription. This is in concordance with previously reported 







































































































the amino acid position to be an important residue contributing to DNA-binding (53). 
Interestingly, a significant decrease of transcriptional activation relative to background level 
was seen in the presence of expressed E47. This could signify a dominant negative effect on 
protein function with an unknown molecular basis, and may potentially explain why this 
variant causes a different ocular phenotype compared to the investigated patient-derived 
variants. 
Heterodimerization stimulates proteasome-dependent degradation 
Co-expression of ATOH7 protein variants and E47 showed a significant reduction in protein 
amounts, which was abolished by the proteasome inhibitor MG-132 (Fig. 3). Interestingly, 
patient variant proteins, and to a lesser extent the previously characterized loss-of-function 
variant p.(Asn46His) and the synthetic variant p.(Ala59Gly), displayed an accelerated 
proteasome-dependent turnover in the presence of E47 (Fig. 4), suggesting an additional 
mechanism by which ATOH7 variants may show reduced function in vivo. 
Proteasome-mediated degradation of ubiquitinated bHLH factors has been observed in 
previous studies (55). Dimerization of several human bHLH proteins, including E47, with the 
C. Elegans HLH-2 has been described as inducing dimerization-dependent proteasomal 
degradation (56). However, compromising protein dimerization by mutating important helix 1 
residues abolished the dimerization-dependent degradation, in contrast to our findings. It is 
possible that although abolished dimerization leads to increased bHLH monomer stability, 
reduced but retained dimerization may lead to the opposite effect due to distorted dimer 
structure or simply to reduced binding of chromatin. The impact of bHLH dimerization on 
protein degradation may indeed depend on multiple factors. A published study reported 
greatly increased stability of bHLH DNA-binding inhibitor proteins (ID proteins) when 
forming heterodimers with E47 (57). The precise mechanisms of how this selective 







































































































ATOH7 mutations as genetic basis for an ocular phenotype dominated by optic nerve 
hypoplasia 
Given the significance of ATOH7 as an early retinal transcription factor specifying RGC fate, 
it is feasible that non-functional ATOH7 mutations lead to a severe reduction in differentiated 
RGCs and therefore affect optic nerve development. Furthermore, we consider the observed 
anomalies of the retinal vasculature, including tortuosity and incomplete peripheral 
vascularization, to be an indirect consequence of reduced RGC differentiation. This is 
supported by the observation that the majority of RGCs in the human retina are generated in 
gestational weeks 7-9 (58), which is followed by the development of the primary retinal 
vasculature at the RNFL/RGC interface at 14-15 weeks of gestation (28). This differentiates 
our findings from exudative vitreoretinopathies, where the primary cause for the vascular 
manifestations is incomplete angiogenesis due to impacted Wnt and Norrin signaling (59). 
In this report we present various characteristics of the addressed ATOH7 patient SNVs that 
culminate in a complete loss of function, thus supporting the hypothesis that p.(Ala59Thr) and 
p.(Ala59Val) are mutations likely causative of the described eye phenotype. This statement is 
based on several observations: 
1) The rare compound heterozygous ATOH7 mutations segregate with ONH in an autosomal 
recessive pattern, 2) both mutations affect the well-conserved 59
th
 amino acid residue within 
the functionally important bHLH domain of ATOH7, 3) the mutations are predicted 
deleterious by three different algorithms, 4) the mutations show significantly increased 
proteasomal degradation and reduction in protein levels, 5) heterodimerization with E47 is 
reduced and consequently E-box DNA-binding of the heterodimer is reduced or abolished, 6) 
complete loss of transcriptional activation induced through the E-box containing promoter, 







































































































proposed schematic model of the functional consequences induced by the p.(Ala59) mutations 
is presented in figure 8. 
As the mutant ATOH7 proteins are likely able to form heterodimers but are functionally 
inactive, it is also possible that they act as dominant-negative proteins in analogy to the Id 
class of bHLH factors (60). The effects of the described ATOH7 mutations could thus have a 
more global effect on the developing retina beyond what it is possible to address in the 
present study. Although this report characterizes several key mechanisms by which loss of 
transcriptional function may occur in the described patient variants, it would be desirable to 
perform functional characterization in an appropriate developmental environment as opposed 
to observations based on transgene expression in a cell line. An animal model or hiPSC-
derived retinal organoid would provide the benefit of addressing transcriptome and DNA 
target alterations, as well as the morphology of RGCs. 
Molecular basis of foveal hypoplasia 
Foveal hypoplasia (FVH) is a reduction in or absence of the foveal pit and foveal avascular 
zone (61). FVH may be diagnosed and graded based on OCT findings (30). Grade one FVH is 
characterized by a shallow foveal pit and the presence of visible extrusion of the inner retinal 
layers. In grade two FVH, the foveal pit is completely absent. Grade three FVH is similar to 
grade two, but without visible outer segment lengthening, whilst in grade four FVH it is not 
possible to visibly differentiate the presumed fovea from the parafovea (30). OCT 
examination of the father revealed a shallow foveal pit and continuity in the outer nuclear 
layer and outer segment, consistent with grade one FVH. Signs of FVH were also found in the 
visually affected siblings suffering from ONH, where the index patient displayed findings 
consistent with grade one FVH and the sister showed a total absence of foveal pit consistent 







































































































Several conditions have been associated with FVH, including ocular albinism, aniridia, and 
achromatopsia (62). Foveal hypoplasia may also present as an isolated trait, commonly in 
association with nystagmus and low vision, although asymptomatic cases as well as cases 
with minor vision deficits have been reported (63–65). Autosomal dominant FVH (OMIM 
#136520) is caused by mutations in PAX6 (40). Although autosomal dominant FVH may 
occur in isolation, it is commonly associated with nystagmus and present in patients with 
aniridia or albinism (66) and sporadically in patients with presenile cataracts (67). Autosomal 
recessive FVH (OMIM #609218) is caused by SLC38A8 mutations (51). A common feature in 
these patients is optic nerve decussation defects and anterior segment dysgenesis in the 
absence of albinism (68). 
In a study examining OCT changes in association with ONH, over 80 % of the investigated 
cases of ONH also presented findings consistent with FVH (69). It is therefore most likely 
that FVH and the vascular abnormalities observed in the affected siblings share a common 
developmental background with ONH in the affected siblings. Conversely, FVH in the 
absence of ONH in the father may be due to a simple heterozygous ATOH7 mutation, 
however we consider this unlikely as the remaining three unaffected family members are 
carrying heterozygous ATOH7 variants affecting the same amino acid residue and the 
unaffected brother is carrying the particular ATOH7 variant. FVH in the father may therefore 
be a result of an unknown independent gene mutation.  
NGS data analysis revealed OPA3 as a possible candidate for FVH. OPA3 encodes an outer 
mitochondrial membrane protein implicated in mitochondrial fission, apoptosis, and 
regulation of lipid metabolism, however the exact function remains to be fully elucidated (70–
72). High expression of OPA3 in the brain, retina, optic nerve, and lens has been observed 
throughout mouse embryogenesis (73). Mutations in OPA3 have been previously linked to 







































































































symptoms, also known as Costeff syndrome (74), as well as autosomal dominant optic 
atrophy 3 with cataract (75). 
The observed OPA3 SNV is shared between the father and the two affected siblings, however 
it is also present in the older unaffected sister. Although segregation of the OPA3 SNV with 
FVH is inconsistent in this family, it may be possible that OPA3 mutations cause FVH with 
incomplete penetrance, analogous to the incomplete penetrance described in autosomal 
dominant optic atrophy (76). An alternative possibility is that FVH occurs as a result of 
combined OPA3 p.(Gly15Arg) and ATOH7 p.(Ala59Val) variants. This specific combination 
of variants is present exclusively in the family members presenting FVH and would explain 
the absence of the FVH phenotype in the other family members. 
Summary 
The presented cases are the first report of compound heterozygous ATOH7 mutations 
associated with a phenotype predominated by optic nerve hypoplasia. Additional findings 
include foveal hypoplasia, as well as vascular abnormalities, which may be a consequence of 
ONH or pleiotropic observations. Analysis of this gene should be performed in patients with 







































































































Materials and Methods 
Optical coherence tomography and fundus imaging 
Macular and circumpapillary optical coherence tomography (OCT) was performed under non-
mydriatic conditions using a single Heidelberg Spectralis® device (Heidelberg Engineering 
GmbH, Heidelberg Germany; software version 6.9a) by one of two authors (JVMH, CG-K), 
both of whom were experienced in acquiring and analyzing OCT data. The following macula 
scan parameters were employed: high resolution (HR) mode; 31 horizontally-aligned sections 
separated by 45 µm covering a retinal area of 30˚ horizontally x 25˚ vertically; 15 Automatic 
Real-Time Tracking (ART) scans averaged per section; centration on the fovea or presumed 
fovea. Circumpapillary scans were acquired with the following scan parameters: HR mode; 
12˚ scan diameter; 100 ART scans averaged; centration on the visible center of the optic nerve 
head. It was necessary to amend the precise OCT acquisition settings used (with the goal of 
reducing the time necessary to acquire OCT data) when scanning the index patient and her 
affected sister, as their reduced visual function (potentially exacerbated by their young age) 
resulted in poor or unstable fixation. Despite this pragmatic approach, it was not possible to 
acquire all OCT scans in both affected patients: in the index patient, only a macula scan could 
be obtained, and then only in the left eye; in the affected sister, a macula scan was 
successfully performed in the right eye only, and circumpapillary scans in both eyes, however 
the scan from the left eye was of insufficient quality (77) and was excluded from further 
analysis. 
All OCT scans were inspected by a single author (JVMH), and the software-generated 
definitions of the inner limiting membrane (ILM) and Bruch’s membrane verified and (when 
necessary) corrected for all sections of the OCT scan. Following this verification, the 1, 3, 6 
mm Early Treatment of Diabetic Retinopathy Study (ETDRS) grid was centered upon the 









































































































from the proprietary software supplied by Heidelberg Engineering. For the circumpapillary 
scans, the software-generated definition of the retinal nerve fiber layer (RNFL) was also 
verified and, when necessary, corrected; global RNFL thickness (averaged from superior, 
inferior, temporal, and nasal quadrants) was obtained from the proprietary software. Macula 
scans were automatically segmented, with author JVMH verifying and, when necessary, 
correcting the software-generated definitions of RNFL, the ganglion cell layer (GCL), and the 
inner plexiform layer (IPL). The macular scan of the index patient was judged to be of 
insufficient quality to reliably distinguish the retinal layers and was thus not segmented. Due 
to the difficulty in accurately distinguishing the border of GCL and IPL, these layers were 
aggregated and subsequently treated as one layer, the ganglion cell-inner plexiform layer 
(GCIPL) (78). Following verification of these intra-retinal boundaries, the 1, 2.22, 3.45 mm 
ETDRS grid was centered upon the fovea or presumed fovea, and GCIPL volume was 
quantified as the sum of the volumes (in mm
3
) of GCL and IPL as obtained from the software 
provided by Heidelberg Engineering. Structural measures of the retinal layers distal to IPL 
were neither verified nor analyzed for the purposes of this study. 
Wide-angle fundus imaging was performed on the affected sister only with the Optomap
®
 
(Optos, Dunfermline, United Kingdom).  
Magnetic resonance imaging 
MRI was performed on a 3-Tesla MR scanner (GE Signa MR750) with an 8-channel head 
coil. The MRI protocol comprised thin-slice (2.5 mm) T2-weighted fat-saturated fast spin-
echo images of the orbits in coronal orientation. 
Whole exome sequencing 
WES was performed with venous blood DNA. Libraries were prepared according to Nextera 







































































































reads. Sequence reads alignment, indexing of the reference genome, and variant calling were 
performed using a pipeline based on BWA at the BaseSpace Onsite (Illumina, San Diego, CA, 
USA). Annotation of the variants was performed using Alamut-batch (Interactive 
Biosoftware, Rouen, France), and variants were visualized on Alamut Viewer 2.3 (Interactive 
Biosoftware, Rouen, France) and Integrative Genomics Viewer 2.6 (79) (Broad Institute and 
the Regents of the University of California, CA, USA). 
In order to identify the most likely disease-causing variants, a variant filtering pipeline was 
utilized according to our previous publication (80). Filtering of variants was performed 
primarily on a set of genes associated with ONH and/or FVH according to Suppl. Table 1, and 
was also extended to a gene panel for eye diseases 
(https://www.medmolgen.uzh.ch/de/services/Hauptgene.html, accessed 01.07.2019) when 
applicable. Owing to the rare occurrence of ONH and FVH in the population, only variants 
with frequency below 1 % were chosen on dbSNP minor allele frequency, 1 000 Genomes, 
Exome Sequencing Projects and Exome Aggregation Consortium. 
Polymerase chain reaction and Sanger sequencing 
Polymerase chain reaction (PCR) targeting ATOH7 exon one was performed by 2-fragment 
PCR. Fragment one was amplified in 25 µl total volume using 1 X Amplitaq Gold™ 360 
Master Mix (Applied Biosystems, Foster City, CA, USA), 1 X 360 GC Enhancer, 0.4 µM 
primers (ATOH7_Ex1_for4 and ATOH7_Ex1_rev2; Suppl. Table 2). Cycling conditions were 
as follows: 95 °C for 15 min; 35 cycles of [95 °C for 1 min, 60 °C for 1 min, 72 °C for 2 
min]; 72 °C for 10 min. Fragment two was amplified in 25 µl total volume using 1.25 U HOT 
FIREPol® DNA Polymerase (Solis Biodyne, Tartu, Estonia), 1 X reaction buffer B1, 1.5mM 
MgCl2, 0.2 mM dNTPs and 0.3 µM primers (ATOH7_Ex1_for2 and ATOH7_Ex1_rev; 
Suppl. Table 2). Cycling conditions were as follows: 98 °C for 2 min; 20 cycles of [98 °C for 







































































































µl total volume using 5 U Phusion® High-Fidelity DNA Polymerase (New England Biolabs; 
Ipswich, MA, USA), 1 X GC buffer, 1 X S-solution (Solis BioDyne, Tartu, Estonia), 0.2 mM 
dNTPs and 0.5 µM primers (OPA3_F and OPA3_R; Suppl. Table 2). Cycling conditions were 
as follows: 98 °C for 2 min; 20 cycles of [98 °C for 10 s, 72 °C for 2 min]; 72 °C for 10 min. 
Sanger sequencing was performed by BigDye Terminator 3.1 (Applied Biosystems, Foster 
City, CA, USA) according to the manufacturer’s instructions using 3130xl Genetic Analyzer 
(Applied Biosystems, Foster City, CA, USA). 
Cloning of expression vectors 
Full-length coding sequence of wildtype ATOH7 (NM_145178.3) was amplified from gDNA 
of a control patient by PCR in 50 µl total volume with 3 U Pfu® Polymerase (Promega, 
Madison, WI, USA), 1 X Pfu buffer, 0.16 mM dNTPs and 0.2 µM primers 
(ATOH7_CACC_FWD and ATOH7_STOP_REV; Suppl. Table 2). Cycling conditions were 
as follows: 95 °C for 2 min; 35 cycles of [95 °C for 45 s, 58 °C for 30 s, 72 °C for 3.5 min]; 
72 °C for 10 min. Human TCF3-E47 cDNA (NM_001136139) was de novo synthesized 
(OriGene, Rockville, MD, USA; cat. RC227647). Expression constructs were created by 
subcloning into pcDNA™3.1/nV5-DEST mammalian expression vector (Invitrogen, 
Carlsbad, CA, USA) expressing either N-terminal V5 tag or C-terminal c-Myc tag.  
ATOH7 variants were constructed by site directed mutagenesis of pcDNA3.1-ATOH7 
construct. PCR reactions were performed by Phusion® High-Fidelity DNA Polymerase as 
described earlier using mutagenesis primers (Suppl. Table 3). PCR products were purified by 
NucleoSpin® Gel and PCR Clean-up (Macharey Nagel, Oensingen, Switzerland), digested by 
DPNI (New England Biolabs, Ipswich, MA, USA) for 2 h and transformed in TOP10 
competent cells (Thermo Fisher Scientific, Waltham, MA, USA). ATOH7 variants were 
verified by Sanger sequencing after which ATOH7 CDS was re-cloned into pcDNA3.1 vector 








































































































Human Embryonic Kidney 293T cells (HEK293T) were cultured at 36.5 °C and 5 % CO2 in 
Dulbecco’s Modified Eagle Medium (Gibco, Waltham, MA, USA; cat. 41966-029), 
supplemented with 10 % Fetal Calf Serum (Eurobio, Courtaboeuf, France) and 1 % 
penicillin/streptomycin (Corning, Corning, NY, USA). Cells were split at 80-90 % 





Transfections were performed using branched Polyethylenimine (PEI; Mw ~25 000; Sigma-
Aldrich, St. Louis, MO, USA) in ratio PEI:DNA 3:1 unless otherwise stated. Cells were 
harvested 24 h post-transfection. 
Immunocytochemistry 
HEK293T were cultured on Poly-L-Lysine pre-coated 22 x 22 mm coverslips inserted into 
six-well plates. Each well was co-transfected with 1.5 µg of pcDNA3.1-V5-ATOH7 and 1.5 
µg of either empty vector or pcDNA3.1-TCF3-c-Myc. A series of three washes with PBS 
were performed between each step. Cells were fixated in 4 % paraformaldehyde (PFA) 
diluted in phosphate buffered saline (PBS) for 15 min, followed by permeabilization in 0.01 
% Triton X-100 diluted in PBS for 20 min. Blocking was performed in 5 % bovine serum 
albumin (BSA) solved in PBS for 30 min.  Primary antibody incubation was performed at 
room temperature for 1 h using rabbit anti-V5 ab (1:200; Suppl. Table 4) and mouse anti c-
Myc ab (1:200; Suppl. Table 4) diluted in blocking solution. Secondary antibody incubation 
was performed at room temperature for 1 h using Alexa Fluor® 488 goat anti-rabbit ab 
(1:1000; Suppl. Table 4) and Alexa Fluor® 647 goat anti-mouse ab, (1:1000; Suppl. Table 4) 
diluted in blocking solution. Coverslips were mounted onto slides using Fluoromount-G® 
(Southern Biotech, Birmingham, AL, USA) containing 4′,6-diamidino-2-phenylindole 
(DAPI). Samples were imaged using a Leica SP8 confocal microscope (Leica Microsystems, 








































































































HEK293T were cultured in six-well plates. Each well was co-transfected with 1.5 µg of 
pcDNA3.1-V5-ATOH7 and 1.5 µg of either pcDNA3.1 vector or pcDNA3.1-TCF3-c-Myc. 
Cells were washed twice with PBS, scraped down, and centrifuged at 1 000 G. Cell pellets 
were resuspended in lysis buffer consisting of 50 mM Tris-HLC (pH7.5), 150 mM NaCl 0.5 
% sodium deoxycholate, 0.1 % sodium dodecyl sulphate; 1 % triton X-100, 1 tabl./50ml 
cOmplete™ protease inhibitor cocktail (Roche; Basel, Switzerland) and incubated for 30 min. 
Whole cell lysate was centrifuged at 14 000 G for 10 min and supernatant was collected. Total 
protein concentration was measured using Pierce™ BCA Protein Assay Kit (Thermo 
Scientific, Waltham, MA, USA) and adjusted to 1 500 µg/ml. Samples were denatured by 
boiling in loading buffer (250 mM Tris, pH 6.8, 10 % sodium dodecyl sulphate, 50 % 
glycerol, 5 % β-mercapthoethanol, 0.5 % bromophenol blue) at 99 °C for 5 min. SDS-PAGE 
was performed in 12.5 % acrylamide gels. Electrophoresis was performed in SDS run buffer 
(125 mM tris, 0.96M glycine, 17.3 mM sodium dodecyl sulphate) at 200 V for 40 min. Gels 
were blotted onto PVDF western blotting membranes (Roche, Basel, Switzerland) in semi-dry 
condition using blotting buffer (48 mM tris, 3.92 mM glycine, 1.30 mM sodium dodecyl 
sulfate, 20 % methanol) at 15 V for 40 min. Blots were blocked in tris-buffered saline 
containing 5 % milk (TBS-T) overnight at 4 °C. Immunoblotting was performed by 
incubation in TBS-T with mouse anti-V5 (1:5000; Suppl. Table 4) or mouse anti-c-Myc ab 
(1:400; Suppl. Table 4) for 1 h and subsequent incubation with sheep anti-mouse HRP-
conjugated ab (1:2000, Suppl. Table 4) for 1 h. Reprobing was performed by two 10 min 
incubations in stripping buffer (0.20 M glycine, 3.47 mM SDS, 1 % ml Tween-20, pH2.2) 
followed by blocking and immunostaining using rabbit anti-β tubulin ab (1:1000; Suppl. 
Table 4) and donkey anti-rabbit conjugated ab (1:2000, Suppl. Table 4). Western lightning 
plus-ECL (PerkinElmer, Waltham, MA, USA) was applied for 1 min to the blots and imaging 







































































































Quantification was performed using Image Lab 5.0 software (Bio-Rad Laboratories, Hercules, 
CA, USA). Relative protein expression was quantified by normalizing to β-tubulin and 
expressed as fold change relative to wildtype ATOH7. Means were calculated from the results 
of three independent measurements (n=3) +/- SD. 
Cycloheximide chase assay 
Cells were treated with proteasome inhibitor MG-132 (Calbiochem, San Diego, CA, USA) 20 
h post-transfection at a final concentration of 20 mM. Cells not treated with MG-132 were 
supplemented with equal volume DMSO (Sigma-Aldrich, St. Louis, MO, USA). 
Cycloheximide (CHX; Sigma-Aldrich, St. Louis, MO, USA), was added 24 h post 
transfection at a final concentration of 100 µg/ml. Cells were collected at 0, 1, 2 and 4 h after 
CHX addition and western blot was performed according to the above described protocol. 
Relative protein expression was quantified by normalizing to β-tubulin and expressed as fold 
change relative to ATOH7 at time point zero. Means were calculated from the results of three 
independent experiments (n=3) +/- SEM. Linear regression was fitted for the time course of 
each variant (dF1,11, p<0.001). Assessment of statistical differences was performed by 
multiple comparisons of the regression slopes using one-way ANOVA corrected for multiple 
comparisons using Tukey’s test and 95 % confidence intervals. 
Protein-protein interaction enzyme-linked immunosorbent assay 
Each incubation was preceded by rinsing wells three times with a wash buffer consisting of 
PBS containing 0.1 % Tween-20. Nunc MaxiSorp™ flat-bottom 96-well plates (Invitrogen; 
Carlsbad, CA, USA) were coated overnight at 4 °C with 2.5 µg/ml mouse anti c-Myc 
monoclonal antibody 9E10 (Suppl. Table 4) diluted in coating buffer (50mM 
carbonate/bicarbonate, pH 9.6). On the following day, unspecific binding sites were blocked 







































































































HEK293T were transfected with 20 µg of either pcDNA-V5-ATOH7, pcDNA3.1-ATOH7-c-
Myc or pcDNA3.1-TCF3-c-Myc construct. Samples were lysed in IP lysis buffer (25 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 1 % NP-40, 1 mM EDTA, 5 % glycerol, protease inhibitor 
cocktail) and centrifuged at 14 000 G for 10 min. Supernatant was collected and total protein 
concentration was normalized to 1 000 µg/ml using Pierce™ BCA Protein Assay Kit (Thermo 
Scientific, Waltham, MA, USA). Lysates containing c-Myc-tagged respectively V5-tagged 
recombinant protein were mixed 1:1 before incubation in prepared ELISA plates overnight at 
4 °C. Primary antibody incubation was performed with rabbit anti-V5 polyclonal antibody 
(1:1000; Suppl. Table 4) diluted in wash buffer for 90 min at 37 °C. Secondary antibody 
incubation was performed with goat anti-rabbit HRP-conjugated antibody (1:1000; Suppl. 
Table 4) diluted in wash buffer for 1 h at 37 °C. Colorimetric detection was performed using 
3,3′,5,5′-Tetramethylbenzidine (TMB; Sigma-Aldrich, St. Louis, MO, USA) and measured at 
690 nm using ELx808™ Absorbance Microplate Reader (Bio-Tek, Bad Friedrichshall, 
Germany). Raw data consisted of kinetic velocity maxima calculated on 100 repeated 
absorbance scans interspaced by 5 s intervals of shaking. Each sample measurement was 
normalized to background measurements consisting of sample detection in plates without 
immobilized c-Myc-tagged dimerization protein. Results were presented as fold change 
relative to the no dimerization control consisting of V5-tagged wildtype ATOH7 and no 
immobilized c-Myc-tagged dimerization partner. Means were calculated from the results of 
three independent experiments, each with three technical replicate measurements (n=3) +/- 
SD. 
DNA-protein interaction enzyme-linked immunosorbent assay 
The following procedure is based on the protocol for protein-protein interaction ELISA. 
Coating with capture antibodies was substituted by 10 µg/ml streptavidin diluted in coating 







































































































and scrambled (scr) E-box dimers were prepared by incubating 0.5 µM of sense and 5-
biotinylated antisense ssODNs (Suppl. Table 5) in STE buffer (100 mM NaCl; 10 mM Tris-
Cl, pH 8.0; 1 mM EDTA) for 5 min at 95 °C and cooling at room temperature for 30 min. 
Wells were incubated with either E-box dimer or scr dimer solution for 1 h at 37 °C. Blocking 
and lysate preparation was performed as above. Samples were incubated by mixing lysate 
from ATOH7 expressing cells with either lysate from negative controls or lysate from E47 
expressing cells. ssDNA from salmon testes (1:50; Sigma-Aldrich, St. Louis, MO, USA) was 
added to samples to reduced unspecific protein-DNA-binding. Primary antibody incubation 
consisting of mouse anti-V5 monoclonal antibody (Suppl. Table 4) for 90 min in 37 °C. 
Secondary antibody incubation consisting of sheep anti-mouse HRP-conjugated antibody 
(Suppl. Table 4) for 1 h in 37 °C.  Each sample measurement was normalized to background 
measurements consisting of sample detection in plates without immobilized E-box DNA. 
Results were presented as fold change relative to scr control consisting of V5-tagged wildtype 
ATOH7 measured in plates containing immobilized scr E-box. Means represent three 
independent experiments each with three technical replicate measurements (n=3) +/- SD. 
Dual luciferase assay 
HEK293T were co-transfected with 43.75 ng of firefly luciferase vector pGL4.23 (Promega, 
Madison, WI, USA) containing seven tandem E-box binding sites (CAGGTG) inserted in 
front of a minimal promoter, 43.75 ng of renilla luciferase control plasmid pGL4.75 
(Promega, Madison, WI, USA), 87.50 ng of pcDNA3.1-V5-ATOH7 construct, and 0.22 ng of 
either pcDNA3.1 vector or pcDNA3.1-TCF3-c-Myc in ratio PEI:DNA 4.5:1. Transcriptional 
activation was determined using Dual-Glo® Luciferase Assay System (Promega, Madison, 
WI, USA) according to manufacturer’s manual. Measurements were performed in 
Luminoskan Ascent (Thermo Labsystems, Helsinki, Finland). Individual firefly luminescence 







































































































were presented as fold change relative to background control consisting of transfections of 
p.GL4.23/4.75 and empty pcDNA3.1 vector or pcDNA3.1-TCF3-c-Myc. Means represent 
three independent experiments each with four biological replicate measurements (n=12) +/- 
SD. 
Statistical analysis 
Calculations and figures were made in GraphPad PRISM v6.07 (GraphPad Software Inc., San 
Diego, CA, USA). Unless stated elsewhere, testing of significance was performed by two-way 
ANOVA comparing simple effects within columns, corrected for multiple comparisons using 
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Table 1 OCT measurements in family members. CRT: central macular thickness; GCIPL: ganglion 
cell and inner plexiform layer volume; LE: left eye; NA: not available; ONH: optic nerve head; RE: 
right eye; RNFL: retinal nerve fiber layer thickness; TMV: total macular volume (in mm
3
). GCIPL 
volume is quantified in mm
3
 over the 1, 2.22, 3.45 mm Early Treatment Diabetic Retinopathy Study 
(ETDRS) grid; TMV is quantified in mm
3
 over the 1, 3, 6 mm ETDRS grid. RNFL is quantified as 
the average (global) thickness over 360˚ in µm.  Gray shading: significantly reduced; black shading: 
thicker than normal. Foveal hypoplasia is graded according to the system proposed by Thomas et al. 
(30). 
Patient Age at examination (years) Eye TMV CRT GCIPL RNFL ONH diameter Foveal hypoplasia 
71877 (mother) 51 
RE 8.64 243 0.79 87 1589 x 1883 NA 
LE 8.62 241 0.8 90 1505 x 1709 NA 
71965 (father) 49 
RE 9.32 300 0.85 104 1589 x 1754 1° 
LE 9.34 302 0.84 104 1635 x 1819 1° 
72447 (sister) 18 
RE 9.84 229 0.86 104 1570 x 1731 NA 
LE 9.68 230 0.87 105 1523 x 1674 NA 
72484 (brother) 14 
RE 9.32 232 0.83 123 1700 x 1623 NA 
LE 9.31 232 0.85 124 1613 x 1786 NA 
72005 (index patient) 11 
RE NA NA NA NA NA (hypoplasia) NA 
LE 7.53 284 NA NA NA (hypoplasia) 1° 
71953 (affected sibling) 7 
RE 7.28 278 0.33 28 NA (hypoplasia) 2° 
LE NA NA NA NA NA (hypoplasia) NA 
 
 
Table 2 Described sequence variations and predicted impact on function. AA; amino acid; MAF: 
minor allele frequency (GnomAD); NFE: non-Finish European. 
RefSeq cDNA variation AA variation MAF (NFE) SIFT MutationTaster2 PolyPhen2 




























































































































Figure 1. A-B: Color fundus images showing a small and dysplastic optic disc and foveal 
hypoplasia associated with abnormal retinal vasculature in both eyes of index patient (A) and 
the affected sibling (B), together with pre-retinal gliotic tissue (B). Upper images are centered 
on the optic nerve; lower images are centered on the fovea; left images represent the right eye; 
right images represent the left eye. C-H: OCT images centered on the fovea show a shallow 
foveal pit and continuity in all retinal layers in the father (C) and the index patient (G), while 
the affected sister (H) shows absence of the foveal pit and continuity in all cell layers. The 
unaffected mother (D) and the older brother (E) and sister (F) show normal OCT findings. I-J: 
Coronal T2w fat-saturated images of patient showing severely hypoplastic optic nerves 
(arrows) with adjacent bright fluid signal within small optic nerve sheaths (I) and small optic 
nerves in the suprasellar cistern (arrows in J). The optic chiasm was not visualized. K-L: MRI 
findings in a healthy five-year-old boy (imaged following facial trauma) are presented for 
comparison, showing normal size of the optic nerves, optic nerve sheaths, and optic chiasm 
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Figure 2. Compound heterozygous missense variants affecting the p.(Ala59) position of 
ATOH7. A: Pedigree of the family with two affected children showing segregation of 
compound heterozygous variants with ONH. B: Sanger DNA sequencing electropherograms 
depicting the compound heterozygous mutations in the two affected siblings. The DNA from 
the unaffected family members is heterozygous for one mutation (M1). C: Sequence 
alignment depicting the two biallelic ATOH7 mutations in the index patient. Vertical bars 
represent sequencing depth (read coverage range shown in the image is 388-440 X). Each 
horizontal bar represents an aligned sequence; only mismatched nucleotides are shown in 








































































































Figure 3. Semi-quantitative western blot of V5-tagged ATOH7 normalized to β-tubulin and 
presented as fold change relative ATOH7 WT. Patient variants display reduced protein 
amounts in the presence of the putative dimerization partner E47 due to proteasome-mediated 
degradation. Each bar represents mean ± SD of three separate experiments. A: Relative 
amount of V5-tagged ATOH7. B: Relative amount of V5-tagged ATOH7 in presence of co-
expressed E47. C: Relative amount of V5-tagged ATOH7 in presence of proteasome inhibitor 
MG-132. D: Relative amount of V5-tagged ATOH7 in presence of co-expressed E47 and 

















































































































Figure 4. ATOH7 protein turnover quantified through semi-quantitative western blot of V5-
tagged ATOH7 normalized to β-tubulin and presented as fold change relative to ATOH7 WT 
before CHX treatment (time point zero). Each point represents mean ± SEM of three separate 
experiments. Fitted lines represent linear regression of protein turnover, showing a negative 
relation between relative protein amount and time (dF1,11 and p<0.001 for all regressions). 
A: Turnover of ATOH7. B: Turnover of ATOH7 in the presence of co-expressed E47. C: 
Turnover of ATOH7 in the presence of proteasome inhibitor MG-132. D: Turnover of 
ATOH7 in the presence of co-expressed E47 and proteasome inhibitor MG-132. Statistical 
differences were tested by multiple comparisons of regression slopes. Star symbols (*) 
represent significance vs. ATOH7 WT and cross symbols (+) represent difference relative the 
previously published loss-of-function variant p.(Asn46His). *, **, ***, **** represent p-















































































































Figure 5. ATOH7 homo and heterodimerization quantified through protein-protein 
interaction ELISA. V5-tagged ATOH7 from cell lysate was bound by immobilized c-Myc-
tagged dimerization partner. Results are normalized to background values (sample, no 
dimerization partner) and presented as fold change relative to untagged control (V5- tagged 
ATOH7 WT, untagged dimerization partner). Bars indicate mean of three independent 
experiments with three technical replicates ± SD. A: Dimerization with immobilized c-Myc-
tagged ATOH7 WT. B: Dimerization with immobilized c-Myc-tagged ATOH7 variants. C: 
Dimerization with immobilized c-Myc-tagged E47. Asterisk symbols (*) represent 
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Figure 6. DNA-binding of ATOH7 quantified through DNA-protein interaction ELISA. V5-
tagged ATOH7 from cell lysate was mixed with lysate containing c-Myc-tagged dimerization 
protein and bound by biotin-streptavidin immobilized E-box DNA. Results are normalized to 
background values (sample, no E-box DNA) and presented as fold change relative to 
scrambled control (ATOH7 WT, scrambled E-box).  Each bar represents mean ± SD of three 
triplicates of three separate experiments. A: V5-ATOH7 DNA-binding in presence of c-Myc-
tagged ATOH7. B: V5-ATOH7 DNA-binding in presence of c-Myc-tagged E47. Asterisk 
symbols (*) represent significance vs. scrambled control. *, **, ***, **** represent p-values 
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, respectively. The pilcrow sign (¶) indicates significant 








































































































Figure 7. Transcriptional reporter gene activation by ATOH7 and its variants quantified 
through dual luciferase assay. HEK293T cells were transfected with plasmid firefly luciferase 
gene expressed under the control of an E-box containing minimal promoter, renilla luciferase 
under the control of a CMV-promoter, and pcDNA3.1 constructs containing ATOH7 or TCF3 
under the control of a CMV-promoter. Firefly luminescence of each sample was normalized 
to renilla luciferase luminescence and is presented relative background control (no ATOH7 
expression) in (A) and relative ATOH7 WT in (B). Bars indicate mean of three independent 
experiments with four biological replicates ± SD. Light grey bars represent luminescence in 
absence of E47; black bars represent luminescence in presence of E47. Asterisk symbols (*) 
represent significance vs. control without E47 expression; cross symbols (+) represent 















































































































Figure 8. A schematic overview of proposed interactions in functional changes of the 
ATOH7 protein as a consequence of non-synonymous p.(Ala59) mutations. Plus (+) and 











































































































ANOVA analysis of variance 
ATOH7* atonal bHlH transcription factor 7 
BBSOAS Bosch-Boonstra-Schaaf Optic Atrophy Syndrome 
BCA bicinconinic acid assay 
bHLH basic helix-loop-helix 
BWA Burrows-Wheeler aligner 
CHX cycloheximide 
DAPI 4′,6-diamidino-2-phenylindole 
E47 transcription factor E2-alpha isoform E47 
ELISA enzyme-linked immunosorbent assay 
EMSA electrophoretic mobility shift assay 
FVH foveal hypoplasia 
GCIPL ganglion cell and inner plexiform layer 
HEK293T human embryonic kidney cell 293T 
HESX1* homeobox expressed in embryonic stem cells 1 
HLH-2 helix-loop-helix 2 
hiPSC human induced pluripotent stem cell 
Math5 mouse atonal homolog 5 
MRI magnetic resonance imaging 
NCRNA nonsyndromic congenital retinal nonattachment 
NEUROD1 neuronal differentiation 1 
NR2F1* nuclear receptor subfamily 2 group F member 1 
OCT optical coherence tomography 
OMIM online mendelian inheritance in man 
ONA optic nerve aplasia 
ONH optic nerve hypoplasia 
OTX2* orthodenticle homeobox 2 
OPA3* optic atrophy 3 
PAX6* paired box 6 
PBS phosphate-buffered Saline 
PCR polymerase chain reaction 
PEI polyethylenimine 
PFA paraformaldehyde 
PFV persistent fetal vasculature 







































































































POU4F2* POU class 4 homeobox 
RetNet Retinal information network 
RGC retinal ganglion cell 
RNFL retinal nerve fiber layer 
RPC retinal progenitor cell 
scr scrambled 
SLC38A8* solute carrier family 38 member 8 
SNP single nucleotide polymorphism 
SNV single nucleotide variant 
SOX2* sex determining region Y box 2 
ssODN single-stranded oligodeoxynucleotide 
TBS tris-buffered saline 
UTR untranslated region 
VAX1* ventral anterior homeobox 1 
WES whole exome sequencing 
* Refers to the gene when italicized, otherwise refers to the protein. 
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